Motixafortide Acetate Suppliers & Bulk Manufacturers
Available Forms: Injection
Available Strengths: 1 mg/mL
Reference Brands: Aphexda (USA)
Category:
Oncology Cancer Care
Motixafortide Acetate is available in Injection
and strengths such as 1 mg/mL.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Motixafortide Acetate is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Motixafortide Acetate can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Motixafortide, marketed under the brand name Aphexda, is a synthetic cyclic peptide that functions as a selective CXCR4 antagonist and hematopoietic stem cell mobilizer. It is primarily used in patients with multiple myeloma to facilitate the collection of hematopoietic stem and progenitor cells for autologous transplantation. Administered via subcutaneous injection, Motixafortide works by blocking the CXCR4 receptor, disrupting the retention of stem cells in the bone marrow, and promoting their release into the peripheral blood.
The drug is indicated for use in combination with filgrastim, a granulocyte-colony stimulating factor (G-CSF), which enhances stem cell mobilization and improves collection efficiency. This combination provides a predictable and effective method for harvesting sufficient stem cells for transplantation. Motixafortide’s rapid onset and targeted mechanism make it a valuable option in clinical settings, offering a controlled and efficient approach to stem cell mobilization for patients undergoing autologous transplant procedures.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing